News & Events

News

Our latest Press Releases

Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025

Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

Tubulis to Present First Phase I/IIa Trial Data for ADC CandidateTUB-040 in Platinum-resistant Ovarian Cancer in Late-breaking Oral Presentation at ESMO 2025

EVENTS

Meet Tubulis live